Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
Serena Masciari(AVEO Oncology (United States)), Judy E. Garber(Dana-Farber Cancer Institute), Alexandra Lebensohn(National Institutes of Health), Jeffrey N. Weitzel(Cancer Genetics (United States)), David Euhus(The University of Texas Southwestern Medical Center), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Melinda L. Telli(Stanford University), Stephen Pochebit(Brigham and Women's Faulkner Hospital), Deborah Dillon(Harvard University), Judith Balmañà(Vall d'Hebron Hospital Universitari), M Rath(Dana-Farber Cancer Institute), James M. Ford(Palo Alto University), Stephen B. Gruber(University of Michigan), Georgios Lypas(Dana-Farber Cancer Institute)
Cited by 189
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k